论文部分内容阅读
Risk of cardiotoxicity is the most serious drawback of anthracycline antineoplastic drugs, which, however, remain among the most powerful and widely used anticancer agents.Early, accurate and preferably non-invasive detection of cardiomyocyte injury is therefore of crucial importance.Cardiac troponins T and I (cTnT and cTnI) are becoming serum biomarkers of choice for monitoring potential drug-induced myocardial injury in both clinical and preclinical studies.Our studies, performed on the validated model of daunorubiein cardiomyopathy in rabbit in vivo, demonstrated that chemotherapy-induced release of cardiac troponins is typically prolonged and continuous.